{"prompt": "['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'throughout the study Eligible subjects at Screening will enter a run in period for 4 weeks', 'during which they continue taking their inhaled COPD medications (excluding ICS and', 'any exclusionary medications). In addition, subjects will be provided with short acting', 'albuterol/salbutamol to be used on as needed basis (rescue medication) throughout the', 'study.', 'Subjects who experience a moderate or severe COPD exacerbation during the run-in', 'period will be deemed run-in failures. Subjects who experience a mild COPD', 'exacerbation, defined as worsening of symptoms that requires no treatment with', 'antibiotics or steroids and is self managed by the patient by an increase of inhaled rescue', 'medication will be able to continue in the study based on the judgment of the investigator', \"and agreement of the sponsor's medical monitor. Subjects experiencing a mild\", 'exacerbation, defined as worsening of symptoms that requires no treatment with', 'antibioties or steroids and is self managed by the patient by an increase of inhaled rescue', 'medication, will be allowed to continue in the study.', 'At the randomization Visit 2 (Day 1), those subjects who successfully complete the run-', 'in period as well as meet the other pre-defined eligibility and randomization criteria will', 'discontinue their inhaled COPD medications and will be randomized to one of the', '3 treatment arms for 24 weeks.', 'All subjects will be given an eDiary for use during the run in, and treatment period to', 'complete PRO questionnaires and record medical problems experienced during the study.', 'Subjects will be performing slow and forced spirometry at specific visits.', 'There will be a total of 5 clinic visits and one follow up phone call (Visit 6). The total', 'duration of subject participation in the study will be approximately 29 to 31 weeks', 'consisting of 2 weeks pre screening if necessary, 4 weeks run in, 24 week treatment and', 'one week Follow Up.', 'In addition, a subset of subjects up to 150 (approximately 150 per treatment arm) will', 'undergo assessment of their physical activity measured through a physical activity', 'monitor (Actigraph GT9X) worn for 7 days from Screening (Visit 1), for 7 days from', 'Randomisation (Visit 2), 7 days from Visit 3, and for 7 days prior to last clinic Visit', '(Visit 5).', 'The occurrence of adverse events (AEs) will be evaluated throughout the study beginning', 'at Visit 2 (Day 1) and until the follow-up contact (Visit 6). Serious adverse events', '(SAEs) will be collected over the same time period as AEs. However, any SAEs', 'assessed as related to study participation (e.g., study treatment, protocol-mandated', 'procedures, invasive tests, or change in existing therapy) or related to a GSK concomitant', 'medication, will be recorded from the time a subject consents to participate in the study', 'up to and including any follow up contact.', 'All subjects will be given an electronic diary (eDiary) for use during the run-in, and the', 'treatment period to complete PRO questionnaires, record COPD daily symptoms and the', 'time they take their COPD medications. Daily rescue medication usage (number of', 'inhalations taken in the last 24h) will also be captured in the eDiary. In addition, and in', '100']['2016N277425_03', 'CONFIDENTIAL', '2018N377698_00', '201749', 'some countries, rescue medication use will also be captured by the use of electronic', 'metered dose inhaler (eMDI).', 'At Screening Visit 1, all subjects must be trained on the proper use of their existing', 'COPD medications inhalation devices and instructed to strictly adhere to and record the', 'time they take their COPD medications in the eDiary.', 'At the randomization Visit 2, all subjects must be trained on the proper use of the', 'ELLIPTA and DISKUS inhalation devices and instructed to strictly adhere to and record', 'the time they take their study medications in the eDiary.', 'All subjects must be trained on the correct use of the eDiary and instructed to complete', 'the eDiary during the run-in and treatment period.', 'There are no plans to routinely provide any of the study treatments for compassionate use', 'following study completion as the study treatment are commercially available.', 'Section 1. Treatment Arms and Duration', 'Rationale for change: clarify stratification and treatment arms', 'Revised text: Subjects will be stratified based on long-acting bronchodilator usage', 'during the run-in (none or one or 2 long-acting bronchodilators per day) and randomized', 'in a ratio of 1:1:1 to either', 'UMEC/VI 62.5/25 mcg once daily via ELLIPTA + placebo twice daily via', 'DISKUS', 'UMEC 62.5 mcg once daily via ELLIPTA + placebo twice daily via DISKUS', 'Salmeterol 50 mcg twice daily via DISKUS + placebo once daily via ELLIPTA', 'Rationale for change: Clarify permitted and prohibited Screening and run-in COPD', 'medications', 'Revised text: *Subjects may continue the use of inhaled LAMAs or LABAs and/or study', 'provided albuterol/salbutamol as needed (rescue medication) Inhaled COPD medications', 'including LABAs, LAMAs or LABA/LAMA combination products are allowed in run in. ICS alone', 'or in combination with a bronchodilator or any exclusionary medications are not allowed.', 'Section 4.1 Study Design', 'Rationale for change: To clarify study design', 'Revised text:', 'This is a multi-centre, randomized, double blind, double-dummy, 3-arm parallel group', 'study. Eligible subjects will be stratified based on long-acting bronchodilator usage', 'during the run in (none, one or 2 long acting bronchodilators per day) and-randomized in', 'a ratio of 1:1:1 to UMEC/VI inhalation powder (62.5/25 mcg once daily) administered', 'via', 'the ELLIPTATM dry powder inhaler, or UMEC (62.5 mcg once daily) administered via', 'the ELLIPTATM or salmeterol (50 mcg BID) administered via the DISKUS.', '101']\n\n###\n\n", "completion": "END"}